Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
Clinical trial NCT06180278 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06180278
- Sponsor
- Amgen
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-02
- Primary completion
- 2028-06-26
- Enrollment
- 32
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.